pumvc3-igfbp2-her2-igf1r
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 2, 2016 (NCT02780401)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pumvc3-igfbp2-her2-igf1r
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02780401 | Phase 1 | Sep 2, 2016 | National Cancer Institute (NCI), University of Washington, University of Wisconsin |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1